A Business at a Glance
0 of 5 daily views used (5 remaining). Sign up free for 10 daily views, or try AAPL for a full preview.
We are a women’s health company utilizing our proprietary proteomics and bioinformatics platform, and significant data resources to improve maternal and neonatal health by discovering, developing, and commercializing blood-based biomarker tests, and predictive analytic products and services. Our vision is to deliver pivotal and actionable information to pregnant women, their physicians, and health care payers to significantly enhance a mother’s pregnancy journey, improve maternal and neonatal health, and reduce health care costs. We believe that our method of combining the disciplines of proteomics and bioinformatics with rigorous clinical testing, data, and economic analysis enables us to provide physicians and expectant mothers with personally insightful, clinically meaningful, and economically impactful information designed to improve the pregnancy experience and outcomes for mothers and babies. There are approximately 140 million births globally each year, and approximately 3.
| Metric | TTM | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Revenue | 95K | - | - | - | - | - |
| Net Income | -33M | -33M | -36M | -44M | -35M | -20M |
| EPS | $-0.76 | $-0.99 | $-1.16 | $-1.43 | $-2.33 | $-12.76 |
| Free Cash Flow | -26M | -14M | -27M | -35M | -33M | -17M |
| ROIC | -75.1% | -68.8% | -51.5% | -44.4% | -25.3% | -96.0% |
| Gross Margin | - | - | - | - | - | - |
| Debt/Equity | 0.00 | 0.00 | 0.00 | 0.01 | 0.00 | -0.00 |
| Dividends/Share | $0.00 | - | - | - | - | - |
| Operating Income | -37M | -37M | -40M | -46M | -35M | -18M |
| Operating Margin | -38918.9% | - | - | - | - | - |
| ROE | -39.7% | -55.8% | -51.7% | -44.7% | -25.3% | - |
| Shares Outstanding | 38M | 33M | 31M | 31M | 15M | 31M |
| Metric | 2020 | 2021 | 2022 | |||
|---|---|---|---|---|---|---|
| Income Statement | ||||||
| Revenue | N/A | N/A | N/A | N/A | N/A | 95K |
| Gross Margin | N/A | N/A | N/A | N/A | N/A | N/A |
| R&D | N/A | N/A | N/A | N/A | N/A | N/A |
| SG&A | N/A | N/A | N/A | N/A | N/A | N/A |
| EBIT | -18M | -35M | -46M | -40M | -37M | -37M |
| Op. Margin | N/A | N/A | N/A | N/A | N/A | -38918.9% |
| Net Income | -20M | -35M | -44M | -36M | -33M | -33M |
| Net Margin | N/A | N/A | N/A | N/A | N/A | -34343.2% |
| Non-Recurring | 0 | 0 | 0 | 0 | 0 | 0 |
| Returns on Capital | ||||||
| ROIC | -96.0% | -25.3% | -44.4% | -51.5% | -68.8% | -75.1% |
| ROE | N/A | -25.3% | -44.7% | -51.7% | -55.8% | -39.7% |
| ROA | -134.1% | -23.8% | -38.0% | -38.0% | -39.2% | -30.2% |
| Cash Flow | ||||||
| Op. Cash Flow | -17M | -32M | -35M | -27M | -14M | -26M |
| Free Cash Flow | -17M | -33M | -35M | -27M | -14M | -26M |
| Owner Earnings | -18M | -35M | -40M | -33M | -22M | -34M |
| CapEx | 149K | 1.3M | 791K | 128K | 56K | 404K |
| Maint. CapEx | 895K | 659K | 756K | 900K | 833K | 833K |
| Growth CapEx | 0 | 645K | 35K | 0 | 0 | 0 |
| D&A | 895K | 659K | 756K | 900K | 833K | 833K |
| CapEx/OCF | N/A | N/A | N/A | N/A | N/A | 0.0% |
| Capital Allocation | ||||||
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 |
| Dividend Yield | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | 0 | 0 | 0 | 0 | 0 | 0 |
| Buyback Yield | N/A | N/A | N/A | N/A | N/A | 0.0% |
| Stock-Based Comp | 726K | 3.1M | 5.1M | 5.3M | 7.0M | 7.0M |
| Debt Repayment | 0 | 3.1M | 0 | 0 | 0 | 0 |
| Balance Sheet | ||||||
| Net Debt | -13M | -105M | -82M | -49M | -46M | -43M |
| Cash & Equiv. | N/A | N/A | N/A | N/A | N/A | 43M |
| Long-Term Debt | 348K | 54K | 626K | 196K | 2K | 2K |
| Debt/Equity | -0.00 | 0.00 | 0.01 | 0.00 | 0.00 | 0.00 |
| Interest Coverage | -9.8 | -47.4 | -748.4 | -724.0 | -1308.4 | -1308.4 |
| Equity | -126M | 139M | 99M | 70M | 48M | 82M |
| Total Assets | 15M | 147M | 116M | 95M | 73M | 108M |
| Total Liabilities | 12M | 8.5M | 17M | 25M | 25M | 2.1M |
| Intangibles | N/A | N/A | N/A | 0 | 2.1M | 2.1M |
| Retained Earnings | -131M | -166M | -211M | -247M | -280M | -280M |
| Working Capital | 2.5M | 102M | 75M | 37M | 23M | 23M |
| Current Assets | 14M | 110M | 90M | 61M | 48M | 48M |
| Current Liabilities | 11M | 8.4M | 16M | 24M | 25M | 25M |
| Per Share Data | ||||||
| EPS | -12.76 | -2.33 | -1.43 | -1.16 | -0.99 | -0.76 |
| Owner EPS | -0.60 | -2.36 | -1.31 | -1.07 | -0.66 | -0.89 |
| Book Value | -4.06 | 9.22 | 3.20 | 2.25 | 1.44 | 2.18 |
| Cash Flow/Share | -0.55 | -2.11 | -1.12 | -0.87 | -0.43 | -0.84 |
| Dividends/Share | N/A | N/A | N/A | N/A | N/A | 0.00 |
| Shares Out. | 30.9M | 15.0M | 30.9M | 31.2M | 33.2M | 37.6M |
| Valuation | ||||||
| P/E Ratio | N/A | N/A | N/A | N/A | N/A | -2.8 |
| P/FCF | N/A | N/A | N/A | N/A | N/A | N/A |
| EV/EBIT | N/A | N/A | N/A | N/A | N/A | N/A |
| Price/Book | N/A | 0.7 | 0.4 | 3.0 | 5.6 | 1.0 |
| Price/Sales | N/A | N/A | N/A | N/A | N/A | 843.6 |
| FCF Yield | N/A | -31.7% | -98.8% | -13.1% | -5.4% | -32.6% |
| Market Cap | N/A | 104M | 36M | 209M | 266M | 80M |
| Avg. Price | N/A | 10.28 | 2.86 | 2.80 | 7.85 | 2.13 |
| Year-End Price | N/A | 6.91 | 1.16 | 6.68 | 8.00 | 2.13 |
SERA PROGNOSTICS, INC. passes 0 of 9 quality checks, indicating weak fundamentals.
SERA PROGNOSTICS, INC. (SERA) has a 5-year average return on invested capital (ROIC) of -57.2%. This is below average and may indicate limited pricing power.
SERA PROGNOSTICS, INC. (SERA) has a market capitalization of $80M. It is classified as a small-cap stock.
SERA PROGNOSTICS, INC. (SERA) does not currently pay a regular dividend.
SERA PROGNOSTICS, INC. (SERA) operates in the Services-Medical Laboratories industry, within the Healthcare sector.
SERA PROGNOSTICS, INC. (SERA) generated $-14 million in free cash flow in its most recent fiscal year. Negative free cash flow may indicate heavy investment or operational challenges.
SERA PROGNOSTICS, INC. (SERA) has a debt-to-equity ratio of 0.00. This indicates a conservatively financed balance sheet.
SERA PROGNOSTICS, INC. (SERA) reported earnings per share (EPS) of $-0.99 in its most recent fiscal year.
SERA PROGNOSTICS, INC. (SERA) has a return on equity (ROE) of -55.8%. A negative ROE may indicate losses or negative equity.
The Ledger Terminal provides 5 years of financial data for SERA PROGNOSTICS, INC. (SERA), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
SERA PROGNOSTICS, INC. (SERA) has a book value per share of $1.44, based on its most recent annual SEC filing.